198 related articles for article (PubMed ID: 26777082)
1. Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases.
Bonney PA; Santucci JA; Maurer AJ; Sughrue ME; McNall-Knapp RY; Battiste JD
J Clin Neurosci; 2016 Apr; 26():161-3. PubMed ID: 26777082
[TBL] [Abstract][Full Text] [Related]
2. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Aguilera D; Mazewski C; Fangusaro J; MacDonald TJ; McNall-Knapp RY; Hayes LL; Kim S; Castellino RC
Childs Nerv Syst; 2013 Apr; 29(4):589-96. PubMed ID: 23296323
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.
Grill J; Geoerger B; Gesner L; Perek D; Leblond P; Cañete A; Aerts I; Madero L; de Toledo Codina JS; Verlooy J; Estlin E; Cisar L; Breazna A; Dorman A; Bailey S; Nicolin G; Grundy RG; Hargrave D;
Neuro Oncol; 2013 Sep; 15(9):1236-43. PubMed ID: 23857707
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric
Chen Z; Tian F; Chen X
Front Public Health; 2022; 10():914536. PubMed ID: 35719637
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.
Aguilera DG; Goldman S; Fangusaro J
Pediatr Blood Cancer; 2011 Mar; 56(3):491-4. PubMed ID: 21072819
[TBL] [Abstract][Full Text] [Related]
6. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
[TBL] [Abstract][Full Text] [Related]
7. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab.
Venkatramani R; Malogolowkin MH; Mascarenhas L
Pediatr Blood Cancer; 2014 Apr; 61(4):756-9. PubMed ID: 24115645
[TBL] [Abstract][Full Text] [Related]
8. Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Massimino M; Casanova M; Polastri D; Biassoni V; Modena P; Pecori E; Schiavello E; De Pava MV; Indini A; Rampini P; Bauer D; Catania S; Podda M; Gandola L
Childs Nerv Syst; 2013 Jul; 29(7):1107-12. PubMed ID: 23595805
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.
Schiavetti A; Varrasso G; Mollace MG; Dominici C; Ferrara E; Papoff P; Di Biasi C
Childs Nerv Syst; 2019 Jun; 35(6):1007-1012. PubMed ID: 30903281
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial.
Levy AS; Krailo M; Chi S; Villaluna D; Springer L; Williams-Hughes C; Fouladi M; Gajjar A
Pediatr Blood Cancer; 2021 Aug; 68(8):e29031. PubMed ID: 33844469
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
Wagner LM; McAllister N; Goldsby RE; Rausen AR; McNall-Knapp RY; McCarville MB; Albritton K
Pediatr Blood Cancer; 2007 Feb; 48(2):132-9. PubMed ID: 16317751
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival in a child with extraneural metastasis from medulloblastoma treated with chemo-radiotherapy.
Paulino AC
Med Pediatr Oncol; 2003 Jun; 40(6):396-7. PubMed ID: 12692812
[No Abstract] [Full Text] [Related]
13. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J
Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
[TBL] [Abstract][Full Text] [Related]
14. Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.
Bautista F; Fioravantti V; de Rojas T; Carceller F; Madero L; Lassaletta A; Moreno L
Cancer Med; 2017 Nov; 6(11):2606-2624. PubMed ID: 28980418
[TBL] [Abstract][Full Text] [Related]
15. Metastatic medulloblastoma in an adult; treatment with temozolomide.
Poelen J; Bernsen HJ; Prick MJ
Acta Neurol Belg; 2007 Jun; 107(2):51-4. PubMed ID: 17710841
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan.
Ku GY; Krol G; Ilson DH
J Clin Oncol; 2007 May; 25(13):e14-6. PubMed ID: 17470852
[No Abstract] [Full Text] [Related]
17. Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma.
Ruggiero A; Rizzo D; Attinà G; Lazzareschi I; Mastrangelo S; Maurizi P; Migliorati R; Bertolini P; Pastore M; Colosimo C; Riccardi R
Eur J Cancer; 2010 Nov; 46(16):2943-9. PubMed ID: 20538454
[TBL] [Abstract][Full Text] [Related]
18. Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma.
Asklund T; Henriksson R; Axelsson J; Bergström Å; Kasper M; Ögren M; Toftgård R; Riklund KÅ
Acta Oncol; 2013 May; 52(4):862-6. PubMed ID: 23013267
[No Abstract] [Full Text] [Related]
19. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
[TBL] [Abstract][Full Text] [Related]
20. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]